News - Proteon Therapeutics
WALTHAM, Mass., April 14, 2011 /PRNewswire/ -- Proteon Therapeutics, Inc. has initiated enrollment in a Phase 2 clinical study of its lead product, PRT-201, in chronic kidney disease (CKD) patients undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis.
WALTHAM, Mass., Nov. 23 /PRNewswire/ -- Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation.
Proteon also receives orphan drug designation for its lead product candidate, PRT-201 WALTHAM, Mass., May 28 /PRNewswire/ -- Proteon Therapeutics, Inc., announced today that it has completed a second closing of its Series B equity financing, securing an additional $12 million and increasing the total equity capital raised in this round to $50 million.